by Katherine Egan Bennett, University of Texas at Arlington Credit: Cell Reports (2023). DOI: 10.1016/j.celrep.2023.113516A multi-institutional study co-authored by University of Texas at Arlington scientists uncovered a mechanism by which cancer cells prevent the immune system from activating and attacking the cancerous invaders. The study, published in Cell Reports, sheds light on why immunotherapy treatments don’t...
by Science China Press The peptide Pal-DMPOP consists a peptide inhibitor of CD47/SIRPα, a D-peptide inhibitor of PD-1/PD-L1, and a palmitic acid tail conjugated at its N-terminal through a PEG4 linker. This design made this peptide resistant to serum proteolysis and accumulated in the tumor tissues. It can block CD47/SIRPα and PD-1/PD-L1 to enhance the phagocytosis...
YALE UNIVERSITY New Haven, Conn. — Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the immune system response against tumors. Immunotherapies that block checkpoint receptors like PD-1, proteins that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer. However,...
CHILDREN’S HOSPITAL OF PHILADELPHIA Philadelphia, May 17, 2023—Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets. The tool, called “Isoform peptides from RNA splicing for Immunotherapy target Screening”...
Graphical abstract. Credit: Cell (2023). DOI: 10.1016/j.cell.2023.02.021 Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells. But new findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes shows that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes. The study, published in...
by Indiana University The platform tracks T cell infiltration of tumor spheroids, which are 3D structures made of cancer cells. Credit: Feng Guo An interdisciplinary team of researchers led by Indiana University bioengineer Feng Guo has developed a tool that could lead to improved cancer immunotherapy. The prototype platform facilitates automated drug screening and real-time,...
by Impact Journals LLC Comparisons of gut microbiome between responders and non-responders from the combined dataset. Credit: Liang et al, Oncotarget (2022). DOI: 10.18632/oncotarget.28252 A new research paper was published in Oncotarget on July 19, 2022, titled “Predicting cancer immunotherapy response from gut microbiomes using machine learning models.” Cancer immunotherapy has significantly improved patient survival. Yet half of patients do not...
Washington State University Credit: Unsplash/CC0 Public Domain A type of white blood cell previously known only as a helper in the immune system appears also to be the instigator of the body’s defenses against cancerous tumors. The discovery could lead to more effective cancer immunotherapy, a promising treatment which uses the body’s own immune system,...
by Ohio State University Comprehensive Cancer Center Killer T cells (magenta) in action against cancer. Credit: Johanna Schafer Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse...
Zhong-Yin Zhang of Purdue’s College of Pharmacy and his team of researchers have developed a cancer immunotherapy. The novel lead compound showed no in vivo side effects and leads to reduced tumor growth in mice studies. Zhong-Yin Zhang. Photo provided by Zhong-Yin Zhang / Purdue University Researchers in Purdue University’s College of Pharmacy are further...
